---
title: "bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285727518.md"
description: "bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M"
datetime: "2026-05-08T12:47:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285727518.md)
  - [en](https://longbridge.com/en/news/285727518.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285727518.md)
---

# bioAffinity Technologies GAAP EPS of -$0.81, revenue of $1.35M


### Related Stocks

- [BIAF.US](https://longbridge.com/en/quote/BIAF.US.md)
- [BIAFW.US](https://longbridge.com/en/quote/BIAFW.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)

## Related News & Research

- [bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 | BIAF Stock News](https://longbridge.com/en/news/286107351.md)
- [Co-Diagnostics Advances Ebola Preparedness With New Bundibugyo Virus Assay Strategy; Stock Up](https://longbridge.com/en/news/286956797.md)
- [Genprex data shows gene therapy reverses hyperglycemia in T2D mice at ASGCT](https://longbridge.com/en/news/286414681.md)
- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Precigen Q1 revenue beats estimates on PAPZIMEOS launch](https://longbridge.com/en/news/286311056.md)